• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Cell Salvage for Cesarean Sections

January 17, 2018

Cell savage, the collection and return of lost autologous blood during surgery, is frequently used in cardiothoracic and vascular surgeries. The use of cell savage in obstetrics, however, has been limited due to the concern of amniotic fluid embolism and RhD hemolytic disease.  In order to evaluate the safety and effectiveness of cell savage, 3,028 pregnant women at risk for hemorrhaging were randomized in a 1:1 ratio to undergo either standard care or routine cell salvage during emergency and scheduled cesarean sections.  Rates of blood transfusions were similar in both groups—3.5% in the standard care group compared to 2.5% in the cell salvage group (adjusted odds ratio 0.65; 95% CI, 0.42 to 1.01, p=0.056).  In addition, fetomaternal hemorrhage was higher among women in the cell salvage group compared to the standard care group (25.6% vs. 10.5%; adjusted odds ratio 5.63; 95% CI 1.43 to 22.14, p=0.013).  Furthermore, cost effectiveness analyses comparing use of cell salvage versus standard care for women undergoing cesarean sections were inconclusive.  The effectiveness of cell salvage may be greater in resource limited locations or situations where red blood cells are scarce.

Reference:

  1. Kahn KS, Moore PAS, Wilson MJ. Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO). PLoSMed; 2017; 14(12): e1002471

Filed Under

  • News

Recommended

  • Universal Donor Red Blood Cells Can Be Genetically Engineered Using CRISPR Gene Editing

  • COVID-19 Pandemic Leading to Blood Supply Shortages

  • Long-term Survival of Severe Trauma Patients Treated with Tranexamic Acid

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

  • Jehovah’s Witness Governing Body Allows Autologous Transfusions

  • RBC Exchange Transfusion for Patients with Severe Babesiosis

  • Oropouche Virus RNA Detected in Blood Donors in Brazil

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley